Tesla Recalls Model...
Health Care: Drugs
Pharmacyclics Incorporated (PCYC: NASDAQ)
$84.70 -3.56 | -4.03%
06/19/13 - 04:00 PM ET
Company Balance Sheet
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 197.90M | 87.76M | 51.20M | 14.53M |
| Receivables | 6.01M | 54.00K | 194.00K | 632.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 213.40M | 114.70M | 76.04M | 17.54M |
| Property, Plant & Equipment, Gross | 12.32M | 10.20M | 9.24M | 9.08M |
| Accumulated Depreciation & Depletion | 8.48M | 8.89M | 8.78M | 8.61M |
| Property, Plant & Equipment, Net | 3.84M | 1.31M | 459.00K | 470.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.88M | 344.00K | 316.00K | 290.00K |
| Total Non-Current Assets | 5.72M | 1.66M | 775.00K | 760.00K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 219.12M | 116.35M | 76.82M | 18.30M |
| Accounts Payable | 9.18M | 5.68M | 2.86M | 1.17M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 18.99M | 14.27M | 10.01M | 15.37M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 410.00K | 0.00 | 0.00 |
| Other Non-Current Liabilities | 68.01M | 0.00 | 50.00K | 4.67M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 68.01M | 410.00K | 50.00K | 4.67M |
| Total Liabilities | 87.00M | 14.68M | 10.06M | 20.04M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 132.12M | 101.67M | 66.76M | -1.74M |
| Common Par | 7.00K | 7.00K | 6.00K | 3.00K |
| Additional Paid In Capital | 533.26M | 514.81M | 444.68M | 361.15M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -401.14M | -413.12M | -377.92M | -362.90M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -9.00K | -21.00K | -6.00K | 1.00K |
| Total Capitalization | 132.12M | 101.67M | 66.76M | -1.74M |
| Total Equity | 132.12M | 101.67M | 66.76M | -1.74M |
| Total Liabilities & Stock Equity | 219.12M | 116.35M | 76.82M | 18.30M |
| Total Common Shares Outstanding | 69.32M | 67.92M | 59.20M | 27.54M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 68.73M | 59.97M | 48.34M | 26.57M |
| Diluted Weighted Shares Outstanding | 72.62M | 59.97M | 48.34M | 26.57M |
| Number of Employees | 150 | 77 | 58 | 46 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with PCYC
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 28
- UserGFNN Stockdiagnostics 20
- ContributorStocks Rising On Unusual Vo...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Best-Performing Stocks i...
- ContributorStocks At New 52-Week Highs...
Latest PCYC Headlines from TheStreet
- Winners And Losers in CLL at ASCO '13 06.10.13 | 07:06 am
- ASCO '13 Live Blog: Prepping for Monday Trading 06.03.13 | 08:06 am
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner 05.31.13 | 05:05 pm
- Making The Call: Pharmacyclics FDA Drug Approval Before Year End 05.29.13 | 08:05 am
- Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Winner 05.23.13 | 05:05 pm
- 5 Stocks Raising The Drugs Industry Higher 05.23.13 | 01:05 pm
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up 05.15.13 | 06:05 pm
- ASCO '13 Preview: Gilead's Big Cancer Debut 05.15.13 | 06:05 pm
- 10 ASCO '13 Abstracts You Can Read Right Now 05.15.13 | 06:05 pm
Press Releases for PCYC
- Pharmacyclics Completes Enrollment Of First Phase III Ibrutinib CLL Study - RESONATEâ¿¢ And Announces Completion Of Enrollment Of Phase II Ibrutinib MCL Study - SPARK - PR Newswire 04.18.13 | 04:04 pm
- Pharmacyclics Triggers Fourth Milestone Payment For Enrollment Of 5th Patient In Frontline Phase III CLL Study - PR Newswire 04.11.13 | 06:04 am
- Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid And Sustainable Disease Control Irrespective Of Age Or High Risk Prognostic Factor - PR Newswire 04.08.13 | 01:04 pm
- Pharmacyclics Announces Third Breakthrough Therapy Designation For Ibrutinib From The U.S. Food And Drug Administration - PR Newswire 04.08.13 | 06:04 am
- Pharmacyclics, Inc. Prices Public Offering Of Common Stock - PR Newswire 03.08.13 | 08:03 am
- Pharmacyclics, Inc. Announces Proposed Public Offering Of Common Stock - PR Newswire 03.07.13 | 04:03 pm
- Pharmacyclics First To Announce Breakthrough Therapy Designation In Oncology From The U.S. Food And Drug Administration - PR Newswire 02.12.13 | 07:02 pm
- Pharmacyclics Announces Date Of Financial Results For Three And Six Months Ended December 31, 2012 And Conference Call - PR Newswire 02.07.13 | 04:02 pm
- Pharmacyclics® Announces Updated Results For BTK Inhibitor Ibrutinib (PCI-32765) At American Society Of Hematology (ASH) Annual Meeting - PR Newswire 12.11.12 | 04:12 pm
- Follow-up Results Of Phase 2 Study Of Investigational Agent, Ibrutinib, Suggest High And Durable Responses In Relapsed/Refractory Mantle Cell Lymphoma - PR Newswire 12.11.12 | 07:12 am
Partner Headlines for PCYC
- Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB) - Benzinga 06.12.13 | 01:06 pm
- Short Interest in Vertex Rises, in Celgene Falls - Benzinga 05.11.13 | 10:05 am
- Amgen, Inc. (AMGN): Today's Most Compelling Stock Buy - NASDAQ 05.09.13 | 04:05 pm
- Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy - NASDAQ 05.07.13 | 05:05 pm
- Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick - NASDAQ 04.26.13 | 07:04 pm
- Biotech Stocks Get A Turbo Boost From Vertex - Seeking Alpha 04.20.13 | 09:04 am
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy - NASDAQ 03.14.13 | 04:03 pm
- Pharmacyclics Is Ripe For A Major Correction - Seeking Alpha 02.16.13 | 06:02 am
- UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence - Benzinga 12.07.12 | 09:12 am
